Lyra Therapeutics receives Nasdaq minimum bid price deficiency notice; has until Jan 15, 2025 to cure

Lyra Therapeutics, Inc.

Nasdaq notified Lyra on July 19, 2024 that its common stock (LYRA) closed below $1.00 for 30 consecutive business days.
Company has 180 calendar days, until January 15, 2025, to regain compliance by closing at or above $1.00 for 10 consecutive days.
If not cured, Lyra may transfer to Nasdaq Capital Market and get an additional 180-day compliance period.
Failure to regain compliance could result in delisting; the company intends to monitor and consider available options.
Stock continues trading on Nasdaq Global Market under symbol LYRA during the cure period.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.